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ABSTRACT 
 
Exon Skipping has been demonstrated to be a successful strategy for 
the gene therapy of Duchenne Muscular Dystrophy (DMD): the 
rational is to convert severe Duchenne forms into milder Becker ones. 
Here we show the selection of U1 snRNA-antisense constructs able to 
confer effective rescue of dystrophin synthesis in a Δ44 Duchenne 
genetic background, through skipping of exon 45; moreover, we 
demonstrate that the resulting dystrophin is able to recover the correct 
timing of myogenic marker expression, to re-localize nNOS and to 
rescue expression of miRNAs previously shown to be sensitive to the 
Dystrophin-nNOS-HDAC2 pathway. 
Becker mutations display different phenotypes, likely depending on 
whether the shorter protein is able to reconstitute the wide range of 
wild type functions. Among them, efficient assembly of the 
dystrophin associated protein complex (DAPC) and Nitric Oxide 
Synthase (nNOS) localization are important. Comparing different 
Becker deletions we demonstrate the correlation between the ability 
of the mutant dystrophin to re-localize nNOS and the expression 
levels of two miRNAs, miR-1 and miR29c, known to be involved in 
muscle homeostasis and to be controlled by the Dys-nNOS-HDAC2 
pathway. 
Since the gene responsible for the disease has been identified, several 
aberrant pathways have been characterized and many therapeutic 
approaches have been proposed to face all the symptoms associated to 
the pathology. What is now quite clear is that the best way to cure the 
disease is to apply different strategies in parallel, to enhance the 
beneficial effect that could be obtained from a single treatment. 
With this concept in mind we identified a microRNA, miR-31, that is 
deregulated in DMD conditions if compared to a healthy control. This 
miRNA represses dystrophin expression by targeting its 3′UTR 
region. In human DMD myoblasts treated with exon skipping, we 
demonstrate that miR-31 inhibition increases dystrophin rescue.  
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These results indicate that interfering with miR-31 activity can 
provide an ameliorating strategy for those DMD therapies that are 
aimed at efficiently recovering dystrophin synthesis. 
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INTRODUCTION 
 
1. DUCHENNE MUSCULAR DYSTROPHY 
 
Duchenne Muscular Dystrophy (DMD) is a severe, X-linked 
neuromuscular disorder affecting 1 in 3500 live males in their early 
childhood (Emery, 1993). It is due to mutations in the dystrophin 
gene that, spanning over 2.5Mb, is one of the largest in the human 
genome.  
DMD has been deeply studied in the last twenty years, since 1986, 
when two independent research groups identified this gene as the one 
responsible for the pathology (Koenig et al., 1987; Monaco et al., 
1986). Studying dystrophin gene and protein, many aspects of its 
structure and functional role have been elucidated, as well as the 
molecular aberrant processes that are involved in the severe 
phenotype of patients. They are usually diagnosed as DMD during the 
first five years of life, when they show difficulties in running, 
maintaining balance, climbing stairs. Then progressive weakness and 
decrease of strength in the limb muscles, force them to the wheelchair 
by the age of twelve. Finally cardiac and respiratory failures lead to 
death within the third decade of life. 
From a histologically point of view, DMD biopsies are characterized 
by the presence of necrotic and degenerating fibers, subject to 
phagocytosis (FIGURE 1). This leads to the infiltration of 
inflammatory cells (macrophages and lymphocytes) and to the 
attempt to replace the damaged tissue with newly formed fibers, 
characterized by a smaller diameter and centrally localized nuclei. 
This regeneration process is possible thanks to a pool of quiescent 
cells, named satellite cells, that undergo activation after muscle 
damage and are able to differentiate in myoblasts and fuse to pre-
existing myotubes. Unfortunately, when the regenerative capacity is 
lost, for the exhaustion of the satellite cell pool, necrotic fibers are 
replaced by adipose and fibrous connective tissue, causing the 
atrophy characteristic of the DMD phenotype.  
Valentina Cazzella 
 8 
 
 
 
 
FIGURE 1 - Histological analysis of DMD muscle. A. Haematoxylin and 
eosin staining of normal muscle (a) and dystrophic muscle (b). In normal 
muscle, myofibres are approximately equal in diameter with nuclei (stained 
blue) located around the periphery. The characteristic features of dystrophic 
muscle are reflective of successive rounds of degeneration and regeneration. 
These include central nuclei (indicated by arrows), a variation in fibre size 
with smaller myofibres present (indicated by arrowheads) and a build-up of 
connective tissue between muscle fibres (indicated by asterisks). B. 
Immunostaining of normal muscle (a) and dystrophic muscle (b) using an 
antibody against the dystrophin protein. Dystrophin is present in the normal 
muscle section (brown staining) and is localized at the sarcolemma (a). 
Nuclei staining in blue. (Adapted from Davies KE et al., 2006). 
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Another form of muscular dystrophy exists, the Becker Muscular 
Dystrophy (BMD, Becker et al., 1955), which is again due to 
mutations in the dystrophin gene but, unlike the DMD mutations, they 
don’t affect the open reading frame of the mature mRNA. As a 
consequence it is usually characterized by less severe symptoms and a 
higher life expectancy. Despite this, a great variance in disease 
severity has been documented over the years (Norman et al., 1990; 
Muntoni et al., 1994): in fact there are patients with a Becker genetic 
background but a Duchenne phenotype, that cannot be justify if we 
don't go deep inside the cause of the disease. 
So, after the discovery of this milder allelic form of dystrophy, many 
efforts have been done to understand why there is such heterogeneity 
of phenotypes among patients affected by the same pathology. To 
answer these questions it is necessary to understand the molecular 
role of the protein and its involvement in cellular pathways 
deregulated in the disease. 
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2. THE DMD GENE AND THE MUTATIONS  
 
Dystrophin protein is encoded by a gene localized to Xp21: it spans 
over 2.5Mb, is transcribed in a 14 Kb messenger RNA (mRNA) made 
of 79 exons. It was identified in 1986 by two groups who were 
studying rare DMD females with translocations X:autosome with the 
breakpoint in Xp21: this identification represented the first example 
of positional cloning (Koenig et al., 1987; Monaco et al., 1986).  
The DMD gene presents three independently regulated and tissue 
specific promoters: they give rise to three full length proteins 
indicated as Dp427M, expressed in skeletal and cardiac muscles; 
Dp427B, active in cortical neurons and hippocampus of the brain; 
Dp427P, present in cerebellar Purkinje cells (Blake et al., 2002). 
There are also four more internal promoters, encoding for smaller 
isoforms that are thought to be involved in the stabilization and 
function of non-muscle dystrophin-like protein complexes (FIGURE 
2). Each of these promoters utilizes a unique first exon that splices 
into exon 30, 45, 56 and 63 respectively, to generate protein products 
of 260 kDa (Dp260), 140 kDa (Dp 140), 116 kDa (Dp116) and 71 
kDa (Dp71). Dp71 is detected in most non-muscle tissues including 
brain, kidney, liver and lung, while the remaining short isoforms are 
primarily expressed in the central and peripheral nervous system 
(Ervasti, 2007; Waite et al., 2012)  
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FIGURE 2 - Protein products of the DMD gene. Schematic diagram 
illustrating the domain structure of the protein isoforms encoded by the 
DMD gene. Dystrophin (DYS) contains an amino-terminal actin binding 
domain (ABD1) consisting of tandem CH domains, a spectrin-like triple-
helical repeat (SR) domain with 4 putative hinge modules (H1–H4) 
interspersed throughout its length, a cysteine-rich (CR) domain critical for 
binding β-dystroglycan, and a carboxy-terminal domain (CT) important for 
binding syntrophins and α-dystrobrevin-2. Acidic spectrin repeats are 
colored red, basic repeats colored blue, and a cluster of basic repeats form a 
second independent actin binding domain (ABD2). Alternate promoters 
drive the expression of four truncated non-muscle isoforms, Dp260, Dp140, 
Dp116, and Dp71 each with unique amino-terminal sequences and the 
indicated domains in common with full-length dystrophin. (Adapted from 
Ervasti et al., 2007). 
 
 
Dystrophin gene is subject to a high mutation rate due to its huge size. 
Most of them are deletions of one or more exons (around 65% of 
cases) or duplications (6%). These mutations usually occur in two 
regions: a major hotspot between exon 45-52, which removes part of  
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the rod domain, and a minor hotspot between exons 2-19, that deletes 
part of the actin-binding and rod domain (Gillard et al., 1989; Oudet 
et al., 1992).  
In 30% of cases, when neither exonic deletion nor duplication can be 
detected, the most common mutations are changes of one or a few 
nucleotides leading to a truncated transcript, either via a premature 
stop codon or the disruption of the reading frame. 
Surprisingly all the mutations described can be responsible of both a 
Duchenne and a Becker phenotype, without a direct correlation 
between the extent of the deletion and the severity of the pathology. 
For example, in several cases the deletion of a single exon is enough 
to cause DMD, whereas deletion of nearly half of the gene (46%) has 
been found in BMD patients (England et al., 1990; Love et al., 1991). 
In the beginning, this observation led to the hypothesis that the rod 
domain could act as a spacer between the actin and the C-terminal 
domain and that it was dispensable. According to this theory 
mutations affecting the size of the rod-domain should be responsible 
only for mild Becker phenotypes. But again it was not enough to 
justify what emerged from clinical studies on BMD and DMD 
patients. This lack of correlation between mutations and phenotypes, 
suggested the so called reading frame hypothesis (Monaco et al., 
1988): if the mutation responsible for the pathology causes a frame 
shift in the open reading frame, the formation of random and 
premature stop codons leads to the degradation of the mRNA and to 
the absence of the protein; on the contrary if the mutation doesn't 
change the correct reading frame, a shorter but still functional protein 
is produced, a protein that is still able to fulfil its structural role.  
However, exceptions to this theory have been described, both for 
DMD patients with in-frame deletions and BMD with out-of-frame 
deletions (Winnard et al., 1993). In-frame DMD-causing mutations 
are either large or remove a domain essential for dystrophin function, 
whereas out-of-frame mutations causing BMD are presumably 
compensated for, either by the use of an alternative start codon or 
exon-skipping leading to an in-frame product (Winnard et al., 1995;  
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Prior et al., 1997). These observations altogether suggest that there 
are some domains of the protein that are not dispensable, whose 
absence causes the inability of a shorten protein to carry out all its 
functions, both structural and not functions. 
The structural functions of the protein can be easily inferred from its 
cellular localization and its peculiar rod shape. On the contrary, its 
role in the intracellular signalling has been elucidated after the 
characterization of the so called Dystrophin Associated Protein 
Complex (DAPC; FIGURE 3). Each member of this complex 
interacts with a specific domain of dystrophin and is involved in the 
multiple functions exerted by the protein. 
 
FIGURE 3 - Dystrophin Associated Protein Complex (DAPC). 
Dystrophin binds to the dystrophin-associated protein complex (DAPC) 
through its C terminus. The DAPC is comprised of sarcoplasmic proteins (-
dystrobrevin, syntrophins and neuronal nitric oxide synthase (nNOS)), 
transmembrane proteins (-dystroglycan, the sarcoglycans, caveolin-3 and 
sarcospan) and extracellular proteins (-dystroglycan and laminin). (Davies 
KE et al., 2006) 
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3. DYSTROPHIN ASSOCIATED PROTEIN COMPLEX 
(DAPC) AND ITS ROLE IN MUSCLE PHYSIOLOGY AND 
PATHOLOGY. 
 
The DAPC consists of cytoplasmic, transmembrane and extracellular 
proteins; it provides a strong mechanical link and mediates 
interactions between the intracellular cytoskeleton and the 
Extracellular Matrix (ECM - Rando, 2001). It is known that mutant 
protein members of the DAPC cause a loss of sarcolemmal integrity 
and therefore render muscle fibers more vulnerable to damage. In the 
absence of dystrophin, for example, the DAPC becomes destabilized; 
the sarcolemma anchorage to the internal actin cytoskeleton and to 
the ECM is lost, with the consequent reduction of the protective role 
of the complex. The increasingly fragile sarcolemma is subjected to 
mechanical injury, which results in progressive muscle-fibre damage 
and sarcolemmal leakage.  
Most of the protein members of the complex are involved in this 
protective and mechanical role: dystroglycans, α-dystrobrevin, 
sarcoglycans, dysferlin and laminin (Cohn et al., 2002; Barton et al., 
2006; Michele et al., 2003). As a consequence, mutations in the genes 
encoding for these proteins, or aberrant post translational 
modifications, are responsible for different muscular dystrophies: 
Limb-Girdle Muscular Dystrophy Type 2D (LGMD 2D, Roberds et 
al., 1994), Left Ventricular Non-Compaction (LVNC, Ichida et al., 
2001), Miyoshi Myopathy (MM, Liu et al., 1998), Merosin-Deficient 
Congenital muscular dystrophy (MDC1A Helbling-Leclerc et al., 
1995). 
Some members of the DAPC, anyway, seem to be involved also in 
intracellular signalling, even if only some pathways have been 
characterized. Among them, the one that has been recently studied 
involves the neuronal Nitric Oxide Synthase (nNOS) and the Histone 
Deacetylases 2 (HDAC2).  
Nitric Oxide (NO) has emerged as a key second messenger molecule 
in several cellular pathways. Its production in muscle is granted by  
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the activity of a neuronal/muscular specific isoform, nNOS, which 
directly interacts with dystrophin in the DAPC (FIGURE 3, Davies 
KE et al., 2006). In DMD muscles dystrophin absence at sarcolemma 
causes the mislocalization of the entire DAPC, including nNOS, and 
the consequent impairing in NO production (Brenman et al., 1995). 
Nitric oxide (NO) is an important vasodilator and regulator in the 
cardiovascular system; it also plays many other regulatory roles, 
including immune function, neural activity, and gastrointestinal 
function. Within skeletal muscle, NO is thought to regulate glucose 
uptake and possibly blood flow during and following exercise 
(McConell et al., 2012). Moreover it is responsible for nitrosylation of 
different proteins, among which HDAC2 has been described (Stamler 
et al., 2001; Colussi et al., 2008).  
Histone deacetylases (HDACs) are a family of enzymes divided in 
four sub-classes based on structural similarities. They are principally 
involved in the withdrawal of acetyl-groups from a large number of 
proteins including nuclear core histones. Their pivotal role in 
regulating the acetylation state of chromatin resulted in a direct 
control of chromatin accessibility and dinamics.  
In particular HDAC2 activity in repressing gene target transcription, 
is negatively regulated by S-nitrosylation on two Cys residues 
(Cys262 and Cys274). These modifications determine conformational 
changes in the enzyme inducing its release from chromatin and a 
consequent increase in chromatin accessibility (Nott. et al., 2008; 
Cacchiarelli et al., 2010). 
In normal skeletal muscles the correct regulation of this enzyme is 
guaranteed by nNOS activity at the sarcolemma. In Duchenne 
pathology, instead, the reduction of NO production due to DAPC 
delocalization, results in a reduced HDAC2 S-nitrosylation, with a 
consequent aberrant deacetylase activity (Colussi et al., 2008). As a 
consequence, different target genes, included follistatin and some 
myomiRs, as mir-1 and miR-29, are down-regulated, promoting 
fibrosis and oxidative stress, usually observed in dystrophic muscles 
(FIGURE 4, Cacchiarelli et al., 2010; Minetti et al., 2006).  
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FIGURE 4 - Model of the pathway connecting dystrophin to specific 
miRNA expression 
In WT muscle fibers the dystrophin/DAPC complex activates nNOS and S-
nitrosylation of HDAC2. The modified HDAC2 is released from the 
chromatin and activation of a specific subset of miRNA occurs. In DMD 
this circuitry is deregulated due to impaired nNOS activity and decrease in 
HDAC2 nitrosylation, causing its retention to miRNA promoters. 
(Cacchiarelli et al., 2010) 
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Dystrophin domain responsible for nNOS correct localization at the 
sarcolemma has been localized in the rod domain (spectrin-like 
repeats 16 and 17) and is encoded by exons 41-46 (Lai et al, 2009). 
As a consequence, BMD patients lacking this part of the protein 
present much more severe DMD-like symptoms than BMD lacking 
other spectrin-like portions of the rod domain.  
So we can conclude that the severity of the pathology can be justified 
by the effect of the mutation on the open reading frame and, among in 
frame mutations, by the role of the lacking domain of the protein in 
ensuring the correct interaction between dystrophin and DAPC 
members. 
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4. CURRENT STATUS OF PHARMACEUTICAL AND 
GENETIC THERAPEUTIC APPROACHES TO TREAT 
DMD 
   
As described above, DMD and BMD symptoms can be very severe. 
Unfortunately a therapy able to restore muscle strength and therefore 
to return a normal life to patients doesn't exist. Thus, even if there are 
currently no curative treatments for this disease, at least the medical 
monitoring and the care coverage of these patients contribute to 
prevention of some complications and to the improvement in their 
quality of life.  
In parallel many efforts have been done to develop a resolutive 
therapeutic strategy for the majority of patients. Among them we can 
distinguish pharmaceutical approaches from gene and cell therapy 
approaches (Pichavant et al., 2011). 
 
Pharmaceutical approaches - The great advantage of a 
pharmacological approach is that nearly all drugs can be delivered 
systemically (orally, intravenously, sub-cutaneously) and thus will 
reach and potentially treat all muscles. Most of the strategies included 
in this category are focused on endogenous dystrophin synthesis 
restoration.  
 
Stop codon read-through. About 10–15% of DMD patients have a 
mutation that converts an amino acid into a premature nonsense 
codon, while the rest of the mRNA is unaffected. Some drugs have 
been shown to enable stop codon read-through by introducing an 
amino acid at the premature stop codon to continue the mRNA 
translation (FIGURE 5). This phenomenon is called “stop codon read-
through”. Gentamicin and Ataluren are two molecules able to interact 
with the ribosome and to induce the inclusion of an aminoacid  when 
a premature stop codon is present. Even if many studies on the mdx 
mouse (murine model of DMD) have been successful for both drugs,  
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phase I and II clinical trials on humans showed less efficacy and some 
toxicity (Hirawat et al., 2007). 
 
 
 
 
FIGURE 5 – Schematic representation of the current therapeutic 
strategies for the cure of DMD. (Adapted from Nelson et al., 2009).  
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Exon skipping. In DMD the deletion of one or more exons can cause 
the formation of a premature stop codon, due to the shift of the 
correct reading frame. But we know that BMD patients lacking even 
wider portions of the gene, can live a normal life, because the 
resulting protein is shorter than the normal one but still functional. 
The exon skipping strategy (FIGURE 6) is based on the use of 
antisense molecules able to interfere with splicing signals, inducing 
the skipping of a specific exon; its exclusion from the dystrophin 
mRNA can restore the open reading frame and allow the expression 
of an internally deleted but functional dystrophin in DMD patients. 
So exon skipping can convert a severe DMD phenotype into a milder 
Becker one. The validity of this approach has been widely 
demonstrated both in the mdx mouse (Mann et al., 2001) and in in-
vitro experiments performed on human DMD myoblasts (Aartsma-
Rus et al., 2005). A great advantage of this approach is the possibility 
of curing different deletions with the skipping of the same exon. This 
way one antisense molecule can be therapeutic for a percentage of 
different patients (see TABLE 1, Aartsma-Rus et al., 2009). 
The molecules used for this purpose are small synthetic modified 
RNAs or DNAs called antisense oligonucleotides (AOs) able to bind 
specific intronic or exonic sites of pre-mRNA. Annealing to selected 
splice motifs, the AO essentially masks the target exon from the 
splicing machinery, thereby promoting specific exon exclusion from 
the mature mRNA. Two types of AO are mainly used: 2′-O-methyl-
phosphorothioate (2OMP, Goemans et al., 2011) and 
phosphorodiamidate morpholino oligomer (PMO, Cirak et al., 2011). 
Both entered clinical trials of phase I and II, with promising results in 
inducing dystrophin synthesis with low toxic effects. 
The use of AOs presents some limits: they are not stable, so reiterated 
administrations are necessary. Moreover it is desirable that antisense 
molecules localize in the correct cellular compartment to obtain 
efficient exon skipping. To fulfill all these requests antisense 
sequences were cloned in the small nuclear RNA U1 or U7 (snRNA) 
and expressed as chimeric molecules. AAV1 coding for the U7 or U1  
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snRNA modified genes targeting the mouse dystrophin exon 23 were 
injected in mdx mice. The expression of the internally deleted 
dystrophin was observed up to 3 months following the injection of an 
AAV1 coding for the U7 snRNA (Goyenvalle et al., 2004) and for at 
least 1 year and half with an AAV1 coding for the U1 snRNA (Denti 
et al., 2008). The efficiency of the approach was demonstrated also in 
human DMD derived myoblasts (Incitti et al., 2010). Clinical data 
about this approach are not yet available.  
 
Myostatin. A potential therapeutic method to improve muscle strength 
is to block myostatin. Myostatin is a member of the transforming 
growth factor-β family implicated in muscle size regulation. Indeed, 
in the myostatin gene knockout mouse, robust muscular hypertrophy 
and hyperplasia are observed. The idea is to use antibodies or knock-
down approaches to inhibit myostatin pathway and increase muscle 
size, perhaps in parallel with one of the treatments described above 
(Malerba et al., 2012). 
 
Pharmacological upregulation of the dystrophin-related protein, 
utrophin. Utrophin is a protein encoded by a gene on chromosome 6 
in humans. The primary structure of utrophin is very similar to that of 
dystrophin, with the N-terminal, cysteine-rich and C-terminal 
domains displaying significant structural similarity, being 80% 
identical to each other (Tinsley et al. 1992). Utrophin shares many of 
the same binding partners as dystrophin. The C-terminus of utrophin 
has been shown to bind to members of the DAPC, such as α-
dystrobrevin-1 (Peters et al. 1998) and β-dystroglycan (Ishikawa-
Sakurai et al. 2004). Unlike dystrophin, which is expressed in muscle, 
with lower levels in brain, utrophin is ubiquitously expressed. 
A range of strategies has been used to upregulate utrophin by 
pharmacological means, and clinical success has been documented 
(Tinsley et al., 2011); the main problem is that this protein can’t fulfil 
all dystrophin functions. 
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HDAC inhibitors. Since the discovery of HDAC2 aberrant activation 
in DMD pathogenesis, different drugs able to inhibit these enzymes 
entered in clinical trials (Consalvi et al., 2011) and have been 
successfully used in order to promote regeneration in dystrophic 
muscle. 
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TABLE 1.  
Overview of the Applicability of Exon Skipping for DMD Mutations 
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A 
 
 
 
B 
 
 
FIGURE 6 - Example of exon-skipping strategy.   
A. Deletion of exon 50 in DMD gene results in an out-of-frame mRNA 
transcript and a prematurely aborted dystrophin synthesis. B. Employing of 
antisense molecules against exon 51 splice sites produce an in frame mRNA 
transcript resulting in a shortened BMD-like dystrophin protein. 
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Gene therapy approaches - Gene therapy in DMD consists of the 
introduction of a functional copy of the DMD gene in muscle fibers, 
with the aim of restoring muscle function, including force generation 
and resistance to muscle contraction induced damage. The concept of 
dystrophin internally deleted genes that would fit the packaging 
capacity of small viral vectors came from clinical observations that 
some BMD patients with internally deleted dystrophins could 
maintain ambulation for many decades. This gave rise to the concept 
of mini-dystrophin (mDYS) or micro-dystrophin (µDys). Gene 
therapy is divided in two distinct categories: those using viral vectors 
to transfer the gene are referred to as “viral gene therapy”; those 
employing naked DNA as “non viral gene therapy”. In both the cases 
the main issue that has to be solved regards the immune response of 
the host organism against the new protein and/or the viral capsid used 
for the delivery (Wang et al., 2000; Acsadi et al., 1991) 
 
Cell therapy approaches - Cell therapy involves the delivery of cells 
able to produce new muscle to diseased areas. These can be either 
muscle precursor cells or stem cells that have the ability to 
differentiate into muscle cells. The cell therapy strategy that has 
experienced the most success so far has been the transplantation of 
myoblasts into diseased tissue; anyway the percentage of colonized 
fiber in different clinical trials was very low, due to the immune 
response of the host organism. Current hopes are based on the use of 
donor genetically modified myoblasts to reduce the patient immune 
response. Moreover the attention of researchers is moving from 
myoblasts to muscle stem cells: satellite cells and mesoangioblasts 
(Dellavalle et al., 2007), the only ones able to repopulate the muscle 
successfully. A big limit of these cell-based strategies is the delivery 
of the cells in every muscle district, in particular heart and diaphragm.  
Stem cell therapy in clinical trial for DMD includes CD133+ 
(Torrente et al., 2007) and mesoangioblasts (Giulio Cossu, in 
progress). 
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AIMS 
 
Duchenne Muscular Dystrophy is a rare and severe genetic disease 
whose gene has been identified since 1986; however, a cure has not 
yet been developed. The main issue to be solved is related to the huge 
size of the entire dystrophin gene (14Kb) that renders quite difficult 
the use of a classical gene therapy approach consisting in gene 
transfer. Moreover, it is becoming clear from recent studies that, even 
if DMD is a monogenic disease, the lack of dystrophin has 
consequences on different pathways involved in muscle homeostasis 
and differentiation. These findings confirm that the protein has not 
only a mere structural role in preserving muscle from degeneration, 
but is involved in intracellular signalling, for example orchestrating 
gene expression through the nNOS-HDAC2 pathway. 
Taking into account all these data, when thinking to a therapeutic 
approach for a so complex disease, researchers should develop a main 
strategy aimed to rescue dystrophin synthesis, applying in parallel 
other treatment able to help the muscle in recovering its physiological 
homeostasis. 
In my PhD I focused my attention on the selection of antisense 
molecules able to induce the skipping of exon 45 of the dystrophin 
gene; this exon is one of the most common, after exon 51, in terms of 
number of patients that can be cured (8.1% of known DMD 
mutations). Δ44 DMD myoblasts, treated with the skipping of exon 
45, were then analyzed to verify the beneficial effects of recovering 
dystrophin synthesis on muscle differentiation. Indeed we 
demonstrated that rescue of dystrophin was able to recover the 
expression of late muscle differentiation marker; moreover even the 
expression of some myomiRs depending on the nNOS-HDAC2 
pathway was rescued, underlying that exon 44 and 45 are dispensable 
for the recruitment of nNOS to the sarcolemma. BMD biopsies were 
then analyzed to correlate the mis-localization of nNOS with the 
expression of miR-1/miR29 and with the clinical phenotype of 14 
patients.  
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Finally a miRNA, miR-31 was identified that is over expressed in 
pathological condition (both in the mdx mouse and in DMD 
myoblasts) and targets dystrophin 3’UTR. We demonstrated that 
decoy of miR-31 could be a valid parallel approach to enhance the 
effect of all those therapies that aim to rescue endogenous dystrophin 
synthesis. 
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RESULTS 
 
Design and expression analysis of antisense molecules against 
exon 45 of the dystrophin gene  
 
Eight constructs, in the backbone of the U1 snRNA, were designed 
and produced for the skipping of exon 45 of the dystrophin pre- 
mRNA (FIGURE 7a, TABLE 1). Nucleotides from position 3 to 10 at 
the 5’end of U1 snRNA, required for the recognition of 5’splice 
sites (Zhuang et al., 1986), were substituted with antisense sequences 
complementary to different portions of exon 45 and splice sites. The 
initial construct (#1) contained antisense sequences against both 
splice junctions, since we previously showed that both splice sites 
have to be targeted in order to induce efficient exon skipping when 
using U1 snRNA (Incitti et al., 2010). Additional constructs were 
produced that contained also antisense sequences against putative 
ESEs, known to represent effective target substrates for efficient exon 
skipping (Aartsma-Rus et al., 2006; Cartegni et al., 2003; Aartsma-
Rus et al., 2005). 
The chimeric U1-antisense sequences were cloned under the control 
of the strong polII U1 snRNA gene promoter and termination 
sequences, and subsequently inserted in the dU3 portion of the 3’ 
long-terminal repeat region of a lentiviral vector plasmid (Bonci et 
al., 2003). 
The expression and stability of the different constructs were tested by 
transfection into the murine myogenic C27 cell line. The relative 
expression was measured by co-transfection with the U16RBE 
(Buonomo et al., 1999) plasmid and normalized for the endogenous 
U2 snRNA. Northern blot analysis indicated that all chimeric 
molecules accumulated at fairly similar levels (FIGURE 7b). 
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FIGURE 7 - Exon 45 skipping  
(a) Schematic representation of the exon-skipping strategy for the human 
Δ44 Duchenne Muscular Dystrophy (DMD) mutation. The table 
summarizes the eight different constructs produced together with the 
corresponding target regions on exon 45 and flanking intron (ss, splice site; 
ESE, exonic splicing enhancer); (b) C27 myoblasts were transfected with the 
different antisense constructs together with the U16-RBE plasmid 
[expressing a 143-nucleotide (nt) long modified U16 snoRNA]. Northern 
blot analysis was performed with probes against the 3’splice site (anti-45), 
U16-RBE (RBE), and U2 snRNA (U2). The two latter hybridizations are 
used to normalize for transfection efficiency and as loading control, 
respectively. 
Valentina Cazzella 
 30 
 
 
 
Dottorato di ricerca in Genetica e Biologia Molecolare 
 31 
 
 
Study of exon skipping activity in human DMD myoblasts  
 
Lentiviral particles for each construct were produced in 293T cells 
and used to transduce DMD myoblasts carrying the deletion of exon 
44 (Δ44, provided by the Telethon Neuromuscular Biobank). In this 
case, skipping of exon 45 allows restoration of the correct reading 
frame and the production of a dystrophin protein 106 aminoacid 
shorter than the wild type. Δ44 cells were infected with comparable 
amounts of the different recombinant lentiviruses. After infection, 
they were induced to differentiate and samples were collected after 10 
days for RNA and protein analysis. Exon 45 skipping (FIGURE 8a, 
upper panel) and antisense expression (FIGURE 8a, middle panel) 
were assessed by RT-PCR analysis, utilizing GAPDH as normalizer 
(FIGURE 8a, lower panel). Dystrophin rescue was assessed by 
Western blot (FIGURE 8b, upper panel) and the relative values, 
normalized on actinin levels, are reported in the histogram. Due to the 
low efficiency of exon skipping and in order to have more 
comparable signals, 50 µg of proteins from Δ44-treated cells (PGK 
and #1 - #8) were loaded in parallel with 10 µg of proteins from 
control cells (CTRL). Myosin heavy chain (MHC) detection was used 
as a marker of muscle terminal differentiation. This analysis revealed 
that constructs #6 and #8, targeting only the 3’splice junction and 
ESE sequences, are poorly active in terms of dystrophin recovery. 
Moreover, #1, targeting the two splice junctions, provided very low 
skipping activity and dystrophin rescue. The importance of the 
simultaneous targeting of splice sites and ESE is shown by constructs 
#3 and #4 that provided the highest rescue of dystrophin synthesis 
(around 5%, see the histogram of FIGURE 8b). Interestingly higher 
levels of dystrophin correlated with increase in the MHC terminal 
differentiation marker (FIGURE 8b, panel MHC). 
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FIGURE 8 - Exon skipping activity.  
a) The amount of exon skipping was calibrated by nested reverse 
transcription-PCR (RT-PCR) on RNA extracted from Δ44 cells infected 
with the antisense-expressing lentiviruses. Unskipped and skipped products 
are indicated on the right. Anti-45 refers to the expression of the antisense 
molecules; GAPDH is used as an internal control. b) Rescue of dystrophin 
synthesis. Upper panel: western blot on proteins from CTRL (10µg + 40µg 
PGK), mock infected Δ44 (PGK-50µg) and exon-skipping Δ44 treated cells 
(#1 to #8–50 µg) probed with anti-dystrophin (DYS), anti-myosin heavy 
chain (MHC) and anti-actinin (ACTN) antibodies. Lower panel: the 
histogram indicates dystrophin levels normalized on actinin signals and 
expressed as percentage of CTRL. 
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Dystrophin levels affect myogenic differentiation 
 
In vitro cultured DMD myoblasts display a delay in the appearance of 
typical myogenic markers (Delaporte et al., 1984); this can be easily 
appreciated when comparing in vitro differentiation of Δ44 myoblasts 
with control ones derived from a healthy individual: FIGURE 9a 
shows that the terminal differentiation marker MHC, already present 
at day 6 of differentiation in control cells, is poorly detectable in Δ44 
cells even at day 10. Notably, when exon skipping was applied, the 
treated DMD myoblasts showed an effective recovery of the timing of 
myogenic marker appearance: FIGURE 9b shows a time course (3, 6, 
and 10 days of differentiation) on mock infected (Δ44-PGK) and 
exon-skipping treated (Δ44#4) Δ44 cells. Dystrophin rescue in 
treated cells was paralleled by a relevant temporal restoration of 
late/terminal differentiation markers; in particular, MHC appeared at 
day 6 similarly to control cells, even if at lower levels, and muscle 
creatine kinase (MCK) at day 3. These results clearly demonstrate 
that, with respect to healthy myoblasts, the delay of appearance of 
late myogenic markers (MHC and MCK) in untreated (Δ44) and 
mock infected (Δ44-PGK) DMD cells is recovered in exon-skipping 
treated (Δ44#4) cells. Moreover, immunostaining analysis of 
FIGURE 9c indicates that the terminal differentiation marker MHC, 
already present at day 8 of differentiation in control cells (CTRL), is 
almost undetectable in mock infected Δ44 cells (Δ44-PGK) at day 
12. At this time point, efficient recovery of MHC staining was 
detected when exon skipping was applied (Δ44#4). 
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FIGURE 9 - Analysis of muscle differentiation markers.  
(a) Western blot on proteins (10µg) extracted from CTRL and Δ44 cells 
probed with anti-dystrophin (DYS), anti-myosin heavy chain (MHC), and 
anti-myogenin (MYOG) antibodies in growth medium (GM) and at 
different days upon shift to differentiation conditions. Actinin (ACTN) was 
used as a loading control. (b) Western blot on proteins (50 µg) extracted 
from Δ44 cells, infected with lentivirus expressing GFP (Δ44-PGK) or with 
the #4 construct (Δ44#4), at different days upon shift to differentiation 
conditions. Western blot was probed with anti-dystrophin (DYS), anti-
MHC, anti-muscle creatine kinase (MCK), and anti-myogenin (MYOG) 
antibodies. Actinin (ACTN) was used as a loading control. (c) 
Immunofluorescence for MHC localization (red) on control myoblasts 
(CTRL) at 8 days of differentiation, in parallel with mock infected (Δ44-
PGK) and exon-skipping treated (Δ44#4) Δ44 DMD cells at 12 days of 
differentiation. DAPI staining for nuclei detection is also shown.  
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To further analyze the link between dystrophin expression and muscle 
differentiation, RNA interference against dystrophin was performed 
on human myoblasts from a healthy control. siRNAs were transfected 
in myoblasts in grow medium and one day after shift to 
differentiation medium. RNA and protein samples were collected at 2 
and 5 days of differentiation. After 2 days of treatment, dys-siRNA 
treated cells (siDYS) showed a significant reduction of dystrophin 
mRNA (residual 61%) that, after 5 days, reached a residual value of 
43% (FIGURE 10a). Dystrophin decrease paralleled that of mRNA 
levels, even if at a lower extent (FIGURE 10b), probably due to the 
well known long half-life of the dystrophin protein. Notably, in 
RNAi-treated cells, both MHC and MCK accumulated at lower 
levels, with MHC being reduced to 42% of control levels at day 5 of 
differentiation; in contrast, early myogenic factors such as myogenin 
and myoD, were not affected by dystrophin reduction both in terms of 
protein and mRNA (FIGURE 10a, b). 
Altogether, these data support the hypothesis that dystrophin is a 
crucial myogenic factor regulating the progression from early to late 
phases of differentiation. 
 
 
 
 
FIGURE 10 - RNA interference against dystrophin.  
Control human myoblasts were transfected with scramble (siCTR) or with 
anti-dystrophin (siDYS) siRNAs and differentiated for 2 and 5 days. (a) 
Western blot was performed with anti-DYS, anti-MHC, anti-MCK, anti-
MyoD, and anti-MYOG antibodies. Actinin (ACTN) was used as loading 
control. (b) Upper panel: The histogram indicates DYS, MHC, MCK, and 
MyoG protein levels normalized on actinin signals. Error bars: means ± SD. 
Lower panel: DYS, MHC, MCK, and MyoG mRNAs relative expression in 
mock (siCTR) MCK, and DMD-siRNA treated (siDYS) human myoblasts 
after 2 and 5 days of differentiation assessed by quantitative reverse 
transcriptase-PCR (qRT-PCR). GAPDH was used as internal control. 
Relative expressions are shown with respect to mock (siCTR) cells, set to a 
value of 1. *P < 0.05, **P < 0.01. 
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Dystrophin rescue and miRNAs expression levels 
 
In order to test whether the dystrophin protein produced in Δ44 
myoblasts through skipping of exon 45, relocalizes and stabilizes 
nNOS, an immunofluorescence assay was performed with nNOS 
antibodies on myoblasts from: healthy control (CTRL), mock-
infected (Δ44-PGK), and exon-skipping treated (Δ44#4) Δ44 cells. 
FIGURE 11 shows the correct localization of nNOS in control 
myotubes, revealed by well-defined increase in sarcolemmal 
labelling. Indeed, this striated staining is almost absent in Δ44-
untreated myoblasts (Δ44-PGK), where only faint diffused 
cytoplasmic staining is visible. These results are in line with the well-
known decrease and delocalization of nNOS in DMD patients 
(Brenman et al., 1995; Kobayashi et al., 2008). Notably, when Δ44 
cells were treated with exon skipping (Δ44#4), they displayed a well 
visible nNOS signal distributed along the fibers. These results 
indicate that the recovery of dystrophin synthesis allows the correct 
relocalization and stabilization of nNOS at the sarcolemma and that 
exons 44 and 45 are dispensable for this function. 
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FIGURE 11 - Analysis of neuronal nitric oxide synthase (nNOS) 
localization exon-skipping treatment. 
nNOS localization analysed by immunofluorescence with nNOS antibodies 
on CTRL, mock-infected Δ44 (Δ44-PGK) and exon skipping Δ44-treated 
cells (Δ44#4) after 10 days of differentiation. Original magnification,×40. 
Bar = 25 µm. 
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It has been previously shown (Cacchiarelli et al., 2010) that the DYS-
nNOS pathway regulates, through the control of HDAC2 activity, the 
expression of a specific subset of miRNAs with specific function in 
muscle terminal differentiation (miR-1 and miR-133) or in muscle-
degenerative processes such as fibrosis (miR-29 and miR-30). 
Conversely, miRNAs expressed in regenerating fibres, such as miR-
31 and miR-206, were shown not to be controlled through this 
pathway. In order to test the dependence of these miRNAs from 
nNOS rescue in exon skipping treated Δ44 myoblasts, quantitative 
reverse transcriptase-PCR was performed on total RNA extracted 
from WT and Δ44 cells either mock infected (PGK) or treated with 
the different antisense constructs (#1 through #8). FIGURE 12 
indicates that in Δ44 myoblasts miR-1 and miR-133 levels are 
strongly reduced with respect to healthy myoblasts (CTRL), in 
agreement with previous observation in Δ48–50 DMD myoblasts; 
however, when exon skipping recovered dystrophin synthesis, 
increase in the levels of both miRNAs was obtained. 
At difference with these miRNAs, miR-31 was upregulated in Δ44 
cells and, upon dystrophin rescue, its expression remained high 
(FIGURE 12). Recently, it has been shown that Duchenne myoblasts 
contain reduced levels of linc-MD1 (Cesana et al., 2011), a long 
noncoding RNA required for muscle differentiation. FIGURE 12 
(lower panel) indicates that also Δ44 myoblasts have low levels of 
linc-MD1; notably, recovery of dystrophin synthesis induced increase 
in linc-MD1 levels. ChIP experiments on linc-MD1 promoter in 
mouse myoblasts indicated that this transcript is not under the control 
of HDAC2 (C. Pinnarò, personal communication); therefore, the 
increase of linc-MD1 upon dystrophin restoration does not directly 
depend on the DYS-nNOS pathway but it is likely due to an indirect 
effect on muscle differentiation, as previously discussed. 
Altogether, these data confirm that the recovery of dystrophin in Δ44 
cells restores nNOS sarcolemmal localization and in turn the 
biosynthesis of those miRNAs that depend on the DYS-nNOS 
pathway. 
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FIGURE 12 - ncRNAs expression upon exon-skipping treatment. 
miRNAs and linc-MD1 expression analysis performed by quantitative 
reverse transcriptase-PCR (qRT-PCR) on RNA extracted from CTRL, 
mock-infected Δ44 (PGK), and Δ44 cells treated with the different antisense 
constructs (#1 – #8) after 10 days of differentiation. U6 small nuclear RNA 
(snRNA) is used as endogenous control. Relative expressions are shown 
with respect to CTRL cells, set to a value of 100 and ncRNA relative 
quantifications are shown on the top of each lane. *P < 0.05, **P < 0 
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Becker Muscular Dystrophy and nNOS 
 
To further correlate the beneficial effects of dystrophin with the 
integrity of the DYS-nNOS pathway, we analysed 14 biopsies from 
Becker patients carrying mutations differently affecting nNOS 
localization (representative examples are shown in FIGURE 13a). 
The expression of miR-1 and miR-29, previously shown to respond to 
the DYS-nNOS pathway, was analysed from total RNA obtained 
from eight of such biopsies. Figure 13c shows that BMD samples 
lacking nNOS (BMD-5, -6, -7, and -8) display low levels of miR-1 
and miR-29 if compared to BMD samples with reduced or normal 
levels of nNOS (BMD-1, -2, -3, and -4), confirming the direct 
correlation between nNOS and specific miRNA expression. 
Interestingly, in agreement with previous work, biopsies lacking or 
having trace levels of nNOS corresponded to patients displaying an 
overall more severe clinical phenotype (FIGURE 13b and Table 2), 
measured as Hammersmith functional motor scale. This scale, that is 
routinely performed in the clinical follow-up of patients, consist in 20 
consecutive motor activities each scored on a 3-point scale (2 to 0) 
and the total test score can range from 0 if the child cannot perform 
any of the items to 40 if all the items are fully achieved. The table 
indicates that in BMD patients the absence of nNOS correlates with a 
worse outcome (patients BMD-5, -6, -9, and -14) with the only 
exception of BMD-7 that show traces of nNOS, low miRNA levels 
but unaffected HFMS score.  
Becker mutations completely lacking nNOS are those missing exons 
45-47 and 45-49 as they more severely disrupt spectrin like repeats 16 
and 17. However, the finding that deletion 45-51 has visible levels of 
nNOS indicates that a direct relationship between primary sequence 
and protein activity cannot be simply made. 
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FIGURE 13 – neuronal Nitric Oxide Synthase (nNOS) localization and 
miRNAs expression in Becker biopsies. 
(a) Dystrophin (DYS) and nNOS localization analyzed by 
immunofluorescence on control (CTRL), BMD-4, and BMD-6 human 
biopsies. Original magnification, ×10. Bar = 100µm. (b) Table summarizes 
exon deletions of the different BMD patients and corresponding nNOS 
levels. (c) Scatterplot showing the expression levels of miR-29c (Y axis) 
and miR-1 (X axis) analyzed by quantitative reverse transcriptase-PCR 
(qRT-PCR) on RNAs extracted from the different BMD biopsies. U6 small 
nuclear RNA (snRNA) is used as endogenous control. Relative expressions 
are shown with respect to healthy individual (CTRL), set to a value of 1. 
Error bars: means ± SD.                         
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miR-31 is upregulated in DMD myoblasts  
 
Microarray analysis on total RNA from WT and mdx muscle 
revealed the deregulation, in pathologic condition, of different 
miRNAs. Among them miR-31 is upregulated more than 60-fold in 
mdx mice if compared with control ones. In situ hybridization 
(FIGURE 14) showed that miR-31 has a preferential localization in 
regenerating myoblasts identified by the characteristic phenotype of 
mononucleated fibres, which are abundant in mdx conditions and 
almost absent in wild type. 
 
 
 
FIGURE 14 – miR-31 in-situ hybridization on WT and mdx 
gastrocnemius sections. 
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We analyzed its expression in our human DMD biopsies and data 
confirmed that miR-31 is more abundant in a dystrophic condition if 
compared to healthy and Becker muscles (FIGURE 15a). miR-31 
remained high in DMD myoblasts induced to differentiate in vitro, 
whereas in human healthy controls its levels decreased with 
progression of differentiation (FIGURE 15b). DMD myoblasts 
appeared to have a higher proliferating ability and a lower 
differentiation potential than control cells. This was shown by the 
presence of PAX7 in growth conditions and by the delayed 
appearance of differentiation markers upon serum withdrawal 
(FIGURE 15c). In control myoblasts, myogenin peaked already at 
day 2 of differentiation, preceding myosin heavy chain and 
dystrophin synthesis; whereas in DMD cells, myogenin appeared 
only at day 4 preceding MHC synthesis, clearly visible at day 6. 
Immunostaining of the same samples confirmed that DMD cells 
express MHC protein at lower levels and later than control cells 
(FIGURE 15c and d). 
These data indicate that the high levels of miR-31 in Duchenne 
muscles is due to the intensive regeneration involving activated 
satellite cells and to the reduced ability of Duchenne myoblasts to 
complete the differentiation programme.  
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FIGURE 15 - miR-31 is expressed in delayed DMD myoblasts. (a) qRT-
PCR of miR-31 relative expression in human muscle biopsies from healthy 
(Ctrl), Duchenne (DMD) and Becker (BMD) donors. (b) qRT-PCR of miR-
31 relative expression in human primary myoblasts from healthy donors 
(Ctrl, black bars) or DMD patients (DMD, grey bars) in growth medium 
(GM) and at the indicated time points after shift to differentiation medium. 
(c) The same cells were analyzed by Western blot for PAX7, myogenin 
(MyoG), Myosin Heavy Chain (MHC) and Dystrophin (DYS).  Actinin 
(ACTN) was used as a loading control. The values are derived from at least 
three independent experiments. Asterisks: p<0.05. (d) Immunofluorescence 
staining with MHC antibodies (red) and DAPI (blue) on Ctrl and DMD 
myoblasts at 4 days after induction of differentiation. 
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miR-31 targets dystrophin mRNA 
 
In silico analysis, performed by comparing mRNA expression 
profiles in wild type versus mdx animals (data not shown), identified 
a large number of predicted targets of miR-31. Notably, the most 
down-regulated mRNAs in mdx muscles encode for proteins involved 
in terminal differentiation, including dystrophin. One putative binding 
site, embedded in a 40 nucleotide region perfectly conserved among 
mammalian species, was identified in the 3’UTR of the dystrophin 
mRNA (FIGURE 16a). Wild type dystrophin 3’UTR (DMD-WT) and 
a derivative mutated in the miR-31 target site (DMD-mut) were fused 
to the luciferase ORF (FIGURE 16b). Enzyme activity was measured 
in C2 myoblasts in endogenous conditions and upon miR-31 
overexpression (FIGURE 16c). The results indicate that miR-31 
repressed luciferase activity only on DMD-WT and that de-repression 
was obtained with LNA oligos against miR-31 and not with control 
scramble LNA. Scramble LNA transfection per se did not affect 
luciferase activities (not shown). Moreover, when cells were treated 
with a sponge-construct containing four binding sites for miR-31 
(Sponge-31, FIGURE 16a and b), luciferase activity resulted higher 
with respect to cells treated with a control construct (FIGURE 17d). 
Release from miR-31 repressing activity was also obtained when cells 
were treated with a LNA oligo complementary to 23 nucleotides 
across the miR-31 target site (protector-31) both in the presence of 
the endogenous miR-31 and in conditions of miR-31 overexpression 
(FIGURE 16e).  
These data indicate that miR-31 targets the 3’UTR of the dystrophin 
mRNA and that repression is prevented either by the use of miR-31 
decoys or by protecting the miR-31 binding site on dystrophin 
mRNA.    
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FIGURE 16 - miR-31 targets dystrophin mRNA.  
(a) Sequences of: the mature miR-31, the conserved 40 nucleotide region of 
the DMD 3’UTR, the decoy sequence of the sponge-31 construct and the 23 
nucleotide LNA protector (Protector-31) covering miR-31 binding site on 
the DMD 3’UTR. miR-31 seed sequence is underlined. (b) Schematic 
representation of: the luciferase constructs containing the wild type 3’UTR 
of the dystrophin mRNA (DMD-WT) and its mutant derivative with a 
deletion of the miR-31 target site (DMD-mut), the sponge constructs 
containing the GFP gene with a control 3’UTR (Sponge-Ctrl) or with the 
same 3’UTR containing four miR-31 decoy sites (Sponge-31). (c) Renilla 
Luciferase activity in proliferating C2 myoblasts transfected with the 
control Rluc vector or DMD-WT or DMD-mut. in combination with the 
plasmid overexpressing miR-31 (pmiR-31) or a control plasmid (Ctrl). Cells 
were also transfected with control (LNA-Scr) or anti-miR-31 (LNA-31) 
LNA oligos. Renilla activity of the Rluc vector was set to a value of 100% 
in all treatments. (d) Renilla Luciferase activity in C2 myoblasts transfected 
with DMD-WT, in the presence of Sponge-Ctrl or Sponge-31 constructs, 
with pmiR-31, or a control plasmid. (e) Renilla Luciferase activity in C2 
myoblasts transfected with DMD-WT alone (Ctrl) or upon miR-31 
overexpression (pmiR-31) in the presence of control (LNA-Scr) or protector 
(Protector-31) LNAs. The values of all experiments are derived from at least 
three independent experiments. Asterisks: p<0.05.
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miR-31 inhibition enhances exon skipping treatment 
 
In vitro differentiation of C2 mouse myoblasts indicated that miR-31 
was expressed at good levels in proliferating conditions (GM) and its 
levels decreased upon differentiation (FIGURE 17a). Synthesis of 
dystrophin was prominent only at day 5 even though transcription 
was already consolidated at day 3. These data reflected the expected 
inverse correlation between the miRNA and its putative target. We 
next tested in C2 myoblasts whether the endogenous synthesis of 
dystrophin correlated to altered levels of miR-31 (FIGURE 17b): 
overexpression was obtained through infection with a lentivirus 
containing the pri-miR-31 expression cassette (miR-31), while 
depletion was obtained via administration of LNA-31 or sponge-31. 
When cells were induced to differentiate, a consistent decrease of 
dystrophin (almost 3-fold) was observed in conditions of persistent 
overexpression of miR-31; on the contrary, increase in dystrophin 
levels was detected when cells were treated with LNA-31 or sponge-
31. In the last two cases, the limited increase (50 and 40% 
respectively) of dystrophin synthesis is likely due to the fact that 
miR-31 levels already start to decrease at 3 days of differentiation 
(FIGURE 17a). In the lower panels of Figure 17b the levels of the 
dystrophin protein are compared with those of its mRNA; in all cases 
dystrophin mRNA levels were not affected by miR-31 modulation, 
indicating that the miRNA acts by repressing translation rather than 
controlling dystrophin mRNA stability. 
DMD myoblasts, from patient with deletion of exons 48-50 were 
infected with the U1#51 construct able to induce skipping of exon 51 
and to rescue dystrophin synthesis (FIGURE 18a and b; Incitti et al., 
2010). In order to check whether dystrophin synthesis could be 
further improved by reducing miR-31 levels, we tested the ability of 
the sponge-31 construct to increase dystrophin levels when infected in 
∆48-50 DMD myoblasts. Figure 18b shows that sponge construct was 
indeed able to increase by 3-fold dystrophin synthesis when exon 
skipping was applied to these cells. Moreover, also the anti-miR-31  
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LNA oligos were able to increase dystrophin synthesis (2-fold) when 
transfected into exon skipping-treated cells. qRT-PCR showed that 
dystrophin mRNA levels were the same in the different conditions, 
similarly to the MCK mRNA.  
 
 
FIGURE 17 - Effects of miR-31 modulation on dystrophin expression. 
(a) Northern (miR-31 and U2) and Western (DYS and ACTN) analyses of 
C2 mouse myoblasts in growth medium (GM) and at 3 and 5 days after shift 
to differentiation medium. The histogram at the bottom shows the relative 
quantification (RQ) of dystrophin protein and mRNA levels referred to the 3 
day point set to a value of 1. (b) Northern (miR-31 and sno55) and Western 
(DYS and ACTN) analyses on C2 myoblasts treated with: lentiviruses with 
control (Ctrl) or miR-31 (miR-31) expression cassettes, control (LNA-Scr) 
or anti-miR-31 (LNA-31) LNA oligos and lentiviruses carrying Sponge-Ctrl 
or Sponge-31. Differentiation was allowed to proceed for 3 days. 
Dystrophin mRNA (DYS mRNA, black bars) and protein (DYS protein, 
white bars) levels were measured from three independent experiments. 
Histograms at the bottom show the relative quantifications (RQ) of 
dystrophin protein and mRNA levels referred to the values of control 
experiments (Ctrl, LNA-Scr and Sponge-Ctrl) set to 1.  
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FIGURE 18 - miR-31 decoy enhances the beneficial effects of exon 
skipping  
(a) Schematic representation of the exon skipping strategy for the human 
∆48-50 DMD mutation. (b) human ∆48-50 DMD myoblasts were infected 
with control (mock) or U1#51 lentiviruses alone or in combination with the 
miR-31 sponge (U1#51 Sponge-31). Alternatively, cells treated with the 
exon skipping construct (U1#51) were transfected with control (LNA-Scr) 
or anti-miR-31 (LNA-31) LNA oligos. Cells were induced to differentiate 
for 5 days and dystrophin quantified by Western blot. Histograms show the 
RQ of dystrophin protein and mRNA levels as well as MCK mRNA levels 
respectively referred to the values of control experiments set to 1. Asterisks: 
p<0.05. 
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DISCUSSION  
 
Inducing exon skipping as a therapeutic approach of DMD relies on 
the concept of converting severe Duchenne phenotypes into the 
milder Becker ones. However, the latter display a large range of 
phenotypes likely reflecting the ability of shorter forms of dystrophin 
to accomplish only a subset of the different functions of the wild-type 
full-length protein. Multiple variables play a role in determining the 
efficiency of internally shortened dystrophins produced in Becker 
patients: these relate to structural properties of the residual dystrophin 
molecules as well as to their capacity to correctly assemble DAPC 
complexes and to relocalize nNOS (Anthony et al., 2011). 
Regarding the former, the spectrin-like repeat region is composed of 
24 modular repeats found in the rod domain. While removing an 
integral repeat is mostly dispensable, deletions that affect the phasing 
of the repeats are associated with less stable and functional dystrophin 
molecules (Harper et al., 2009). Concerning the role that different 
internal dystrophin deletions have on assembly of DAPC proteins, we 
have recently demonstrated that BMD dystrophins of patients with 
deletions located around exon 51 and 53 are more efficient in re-
localising at the sarcolemma β−destroglycan and α−sarcoglycan 
compared to other deletions that remove spectrin-like repeats 16 and 
17 (Anthony et al., 2011). There is also a strong correlation between 
deletions of spectrin-like repeats 16 and 17 and ability to localize 
nNOS at the sarcolemma (Wells et al., 2003; Lai et al., 2009). 
These are crucial points when thinking of possible therapeutic 
benefits of exon skipping in different DMD mutations and suggest 
that dystrophin rescue should be tested together with correct recovery 
of the entire complex of proteins at the sarcolemma. We have recently 
shown that in DMD mutants lacking exons 48–50, further skipping of 
exon 51 is able to relocalize α-sarcoglycan and nNOS (Cirak et al., 
2012). 
The relevance of nNOS was previously shown to rely on its ability to 
control gene expression through nitrosylation of HDAC2. 
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The rescue of this pathway in dystrophic animals has been proved to 
ameliorate the dystrophic phenotype and to influence the expression 
of a specific subset of genes playing a crucial role in the control of 
muscle terminal differentiation and tissue homeostasis (Cacchiarelli et 
al., 2010): among them, those coding for relevant myogenic miRNAs 
(miR-1 and miR-133) and for species controlling fibro-adipocitic 
degeneration (miR-29 and miR-30). These data suggested that nNOS 
activity plays an important role in muscle homeostasis via its ability 
to directly regulate the expression of specific HDAC2 target genes 
and to have a positive effect on differentiation. 
In this work, we produced antisense molecules, raised in the U1 
snRNA backbone, able to induce effective skipping of exon 45 that is 
one of the most common, after exon 51, in terms of number of 
patients that can be cured (8.1% of known DMD mutations). We 
showed that rescue of dystrophin provided a considerable 
enhancement of differentiation in DMD myoblasts, well characterized 
for their delay in reaching a mature molecular and morphological 
phenotype. This evidence was further supported by experiments of 
RNAi against dystrophin in myoblasts from healthy individuals. In 
this case an evident delay in timing of myogenic markers synthesis 
was observed. Notably, while having such a clear effect on late 
differentiation markers, dystrophin did not show any specific effect 
on timing and levels of early myogenic markers such as Myogenin 
and MyoD. 
The dystrophin protein, obtained through skipping of exon 45 in a 
Δ44 genetic background, produced efficient rescue of nNOS 
localization at the membrane, together with recovery of miR-1 and 
miR-133 expression, indicating the reactivation of the DYS-nNOS 
pathway. In line with the relevance of this pathway, nNOS analysis of 
different Becker individuals indicated that those lacking correct 
localization of the enzyme had a more severe clinical phenotype as 
well as reduction of those marker miRNAs depending on the DYS-
nNOS pathway. 
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Altogether, these data demonstrate a crucial role of dystrophin in 
regulating the switch between early and late phases of muscle 
differentiation and point to the relevance of the DYS-nNOS pathway 
in DMD and BMD. 
It is well known that DMD is a monogenic disease due to mutations 
in the dystrophin gene; but the absence of the protein, as discussed 
before, has multiple effects on different pathways involved in muscle   
homeostasis and differentiation. For this reason, when thinking of a 
possible therapeutic approach, we should prefer a strategy able to 
restore dystrophin synthesis, exon skipping for example, but we can 
combine it with other corollary treatments (HDAC inhibitors, 
corticosteroids, physiotherapy) that can improve the effect of the 
main approach. 
We described miR-31 as part of circuitries controlling late muscle 
differentiation by repressing dystrophin synthesis and, likely, many 
other terminal differentiation markers: for example miR-31 was 
described to repress Myf5 both in muscle and brain (Daubas et al., 
2009; Crist et al., 2012).   
miR-31 repressing activity was detected in early phases of myoblasts 
differentiation supporting the idea that this control is necessary in 
normal muscle cells to avoid early expression of late differentiation 
markers and, specifically, dystrophin. 
The intense and localized expression of miR-31 in regenerating 
myoblasts of dystrophic muscles indicated that the high levels of 
miR-31 found in dystrophic conditions (both in mouse and human 
biopsies) are due to the intensive regeneration program that is 
mediated by the activation of satellite cells. Interestingly, in 
dystrophic myoblasts and satellite cells the lack of dystrophin 
correlated with a delay of the maturation process of the cells.  
In this study we have also shown that in dystrophic conditions, when 
dystrophin synthesis is rescued through the exon skipping strategy, 
the inhibition of miR-31 activity increased dystrophin production. 
Since in a compromised muscle the contribution to dystrophin 
production by regenerating fibers is quite relevant, miR-31 repression  
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in this compartment can represent an improvement to current 
therapeutic treatments aimed to increase the levels of dystrophin 
synthesis. Rescue of consistent levels of dystrophin will also have 
additional benefits such as the completion of muscle fiber maturation 
process. 
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MATERIALS AND METHODS 
 
Antisense clones construction. Clones U1-45 were obtained by 
inverse PCR on the construct pCCL-5′3′Esx (Incitti et al., 2010). The 
oligos utilized are: 
 
U1-45#1: 
F:(5’CAGAAAAAAGAGGTAGGGCGACAGGGCAGGGGAGAT
ACCATGATC 3’) 
R:(5’CCTGGAGTTCCTGTAAGATACCAAAAAGGCATGAGAT
CTTGGGCCTCTGC3’) 
 
U1-45#2: 
F:(5’GCCCAATGCCATCCTGGAGTTCCTGGGCAGGGGAGATA
CCATGATC 3’) 
R:(5’TCCTCAAAAACAGATGCCAGAAGAGGTAGGGCGATGA
G ATCTTGGGCCTCTGC 3’) 
 
U1-45#3: 
F:(5’GCTGCCCAATGCCATCCTGGAGTTCCTGGGCAGGGGAG
ATACCATGATC 3’) 
R:(5’CAGCAATCCTCAAAAACAGATGCGAGGTAGGGATGAG
ATCTTGGGCCTCTGC 3’) 
 
U1-45#4: 
F:(5’GAGGTTGCTGCCTGGAGTTCCTGTAAGGGCAGGGGAG
ATACCATGATC 3’) 
R:(5’AAAAACAGAGAAAAAAGAGGTAGGGCGATGAGATCTT
GGGCCTCTGC 3’) 
 
U1-45#5: 
F:(5’ATTGCCCAATGCCATCCTGGAGTTCCTGTGGCAGGGGA
GATACCATGATC 3’) 
R:(5’CCTCAAAAACAGAGAAAAAAGAGGTAGGGATGAGATC
TTGGGCCTCTGC 3’) 
Dottorato di ricerca in Genetica e Biologia Molecolare 
 57 
 
 
U1-45#6:  
F:(5’GCTGCCCAATGCCATCCTGGAGTTCCTGTAAGGGCAGG
GGAGATACCATGATC 3’) 
R:(5’CAGCAATCCTCAAAAACAGATGCATGAGATCTTGGGC
CTCTGC 3’) 
 
U1-45#7: 
F:(5’GCTGCCCTGCCTCCTGGAGTTCCTGTAAGGGCAGGGGA
GATACCATGATC 3’) 
R:(5’CAGAAAAAAGAGGTAGGGCGACAGATGAGATCTTGGG
CCTCTGC 3’) 
 
U1-45#8: 
F:(5’CCTGGAGTTCCTGTAAGATACCAAAAAGGCGGCAGGG
GAGATACCATGATC 3’) 
R: (5’ATGGCATTGGGCAGCATGAGATCTTGGGCCTCTGC 3’) 
 
C27 transfections 
C27 cells were plated on 3,5 cm diameter plates and co-transfected 
with 3 µg of the lentiviral vector carrying the antisense expression 
cassette and 1 µg of U16RBE plasmid used as a transfection 
efficiency control. Transfection was performed according to the 
Lipofectamine 2000 protocol (Invitrogen, Carlsbad, CA). Cells were 
grown in Dulbecco’s modified Eagle’s medium 10% fetal bovine 
serum for 36 hours and then harvested with 1 ml of QIAzol Lysis 
Reagent (Qiagen, West Sussex, UK). 
 
RNA preparation and analysis 
Cells were harvested with 1 ml of QIAzol Lysis Reagent (Qiagen) 
and biopsies were homogenized with a rotor-stator homogenizer in 
the presence of QIAzol Lysis Reagent (Qiagen). RNAs were 
extracted by miRNeasy (Qiagen), following manufacturer’s 
specifications; concentration was assessed with Nanodrop ND-1000 
Spectrophotometer (CELBIO, Pero, Milan, Italy).  
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qRT-PCR were performed using miScript System (Qiagen). 
 
Northern Blot 
Antisense expression was analyzed by Northern blot as previously 
described (Incitti et al., 2010) using the following probe: anti-45 (5’-
CAGGAACTCCAGG-3’). 
 
Primary myoblasts cultures 
Cultures of primary myoblasts (WT-9808 and Δ44-9981 from the 
Telethon Neuromuscular Biobank) were first pre-plated in order to 
separate fibroblasts from the primary line, then seeded in Human 
Skeletal Muscle Growth Medium (PromoCell, Haidelberg, Germany) 
and grown in a humidified incubator, at 5% CO2 and 37°C. 
 
Virus preparation and cell transduction 
Viruses were prepared as described (Incitti et al., 2010). The day 
before transduction, myoblasts were seeded in Growth Medium, on 6 
cm plates (at least two for each different virus), at a density of 5 x 105 
cells per plate. The next day cells were infected once with lentiviruses 
and polybrene (4 mg/ml). Two days after infection, cells were 
induced to differentiate with Human Skeletal Muscle Differentiation 
Medium (PromoCell). After 10 days of differentiation, cells were 
washed twice with complete PBS buffer (PromoCell) and collected 
with 300 microliters of protein buffer (100 mM Tris-HCl pH 7.4, 1 
mM EDTA, 2% SDS, 1x Complete EDTA- free Protease Inhibitor 
Cocktail (Roche, Applied Science, Mannheim, Germany) for protein 
extraction, or with 1 ml of QIAzol Lysis Reagent (Qiagen) for RNA 
extraction. 
 
RT-PCR 
Dystrophin mRNA was analyzed by RT-PCR (Access RT-PCR 
system – Promega, Madison, WI) on 200 ng of total RNA with oligos 
E42F (5’-GAAGACATGCCTTTGGAAATTTCT-3’) and E48R (5’- 
CTGAACGTCAAATGGTCCTTC-3’). 4µl of the RT-PCR products  
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were then used as template for a nested reaction performed with oligo 
E43F (5’-CTACAACAAAGCTCAGGTCG-3’) and E46R (5’- 
CTCTTTTCCAGGTTCAAGTGG-3’). 
Antisense expression was analyzed by RT-PCR (SuperScript® 
VILOTM cDNA Synthesis Kit -Invitrogen) on 50 ng of total RNA 
with oligos U1primer (5’- CAGGGGAAAGCGCGAACG-3’) and 
RT45 (5’- ATCCTGGAGTTCCTGTAA-3’). GAPDH was used as 
loading control (oligos: F 5’- GGAAGGTGAAGGTCGGAGTC-3’;R 
5’-TTACCAGAGTTAAAAGCAGCCC-3’). 
10 µl of the reactions were run on a 2% agarose-ethidium bromide gel 
and signals were revealed on a UV transilluminator. 
 
Western blot analysis 
Western blot analyses were carried out as previously described.28 
Primary antibodies: anti dystrophyn (NCL-DYS1 Novocastra, New 
Castle upon Tyne, UK, 1:40 in 3% milk); anti myosin (anti-MF-20, 
1:20 in TBST), anti muscle creatine kinase (MCK sc-15161, Santa 
Cruz biotecnology, Santa Cruz, CA) 1:500 in TBST); anti myogenin 
(MyoG sc-12732, 1:1000 in TBST); anti MyoD (DAKO, Glostrup, 
Denmark, 1:500 in 3% milk); anti actinin (ACTN sc-15335, 1:1000 in 
TBST). Secondary antibodies: ImmunoPure®Goat Anti-Rabbit IgG 
Peroxidase Conjugated (PIERCE, Rockford, IL, 1:5000 in 5% milk); 
ImmunoPure®Goat Anti-Mouse IgG Peroxidase Conjugated 
(PIERCE, 1:10000 in 5% milk); donkey anti-goat IgG-HRP (sc- 
2020, diluted 1:5000 in 3% milk). 
 
RNA interference against dystrophin 
The WT 9808 cell line, obtained from Telethon Genetic Biobank 
Network, was grown to 70% confluence on 6 cm plates in Dulbecco’s 
modified Eagle’s medium with 18% fetal bovine serum. Transfection 
was performed twice with 200 pmol of siRNA oligonucleotides 
targeting the dystrophin gene (Qiagen, target sequence: 5’-
AATAACTTGCCATTTCTTTAT-3’) or 200 pmol of siRNA 
negative control using lipofectamine (Invitrogen) according to  
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manufacturer's specification. After 18 hours, the medium was 
replaced. RNA and protein samples were collected after 2 and 5 days 
of differentiation. 
 
Patients 
Fourteen BMD patients, aged from 2 to 15 years, were assessed by 
physiotherapists to quantify muscular strength through Hammersmith 
motor ability score (Scott et al., 1982). Skeletal muscle biopsies were 
obtained, with informed consent, from all BMD patients along with 
non- myopathic control. BMD-3, BMD-4, BMD-6, BMD-9, BMD-
10, BMD-11, BMD-12, BMD-13, BMD-14 and control were obtained 
from Laboratory of Molecular Medicine, Department of 
Neuroscience, Bambino Gesù Children's Hospital, Rome whereas 
BMD-1, BMD-2, BMD-5, BMD-7, BMD-8, BMD-15 biopsies were 
obtained from Dubowitz Neuromuscular Centre, Institute of Child 
Health and Great Ormond Street Hospital, London. 
 
Immunohistochemistry 
Muscle biopsies were mounted in OCT medium. Serial 7 µm 
transverse cryosections were fixed for 15 minutes at 4 °C in 4% 
paraformaldehyde (Electron microscopy Sciences, Hatfield, PA), 
permeabilized with Triton 0,2%/1%BSA/PBS for 15 minutes and 
subsequently blocked in 10% Goat Serum/1%BSA/PBS for 1 h at 
room temperature. Sections were incubated at 4°C with primary 
antibodies diluted in 5% Goat Serum/PBS (incubation buffer) for 16h. 
After serial washes in 0,2% Triton /PBS, secondary antibodies (Goat 
anti-Mouse IgG AlexaFluor 488, Invitrogen or Cy3 conjugated, 
Jackson ImmunoResearch, Inc., Pennsylvania) diluted 1:500 with 
incubation buffer were added for 1h at room temperature. The 
specificity of immunolabeling was verified in control samples 
prepared with the incubation buffer alone, followed by the second 
conjugated antibody. The sections were counterstained with 1.5 
mg/ml 4′,6-Diamidino-2 phenylindole in Vectashield Mounting 
Medium (Vector Laboratories, Inc., Burlingame, CA). Cultured cells  
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were fixed in Methanol/Acetone for 20 minutes at -20°C, 
subsequently air-dried and after brief rehydration with PBS processed 
for immunostaining with primary antibodies (diluted in 1% Goat 
Serum/PBS) as described above. 
Primary monoclonal antibodies used in this study were diluted as 
follows: anti-Dystrophin NCL-DYS2, Novocastra Laboratories 
(diluted 1:12.5); anti-Nos-1 sc-55521 (diluted 1:50), anti-MHC from 
hybridoma supernatants. 
 
Image acquisition and analysis 
Immunostained cells and muscle sections were examined using a 
Zeiss AxioObserver A1 inverted fluorescence microscope equipped 
with Axiocam MRM R camera and Plan-Neofluar EC 10X/0,3 M27 
and LD 40X/0,6 M27 objectives. The images were acquired with 
AxioVision Rel.4.8 imaging software. 
 
Luciferase constructs and assays. 
Full-length murine DMD- 3’ UTR sequence (DMD-WT, 2,461 
bp) was amplified by polymerase chain reaction and then 
cloned in NotI restriction site of the psicheck2 plasmid (Promega), 
downstream from the renilla luciferase (RLuc) gene. The same 
plasmid also contains the firefly luciferase (FLuc) to normalize 
transfection efficiency. Mutant derivative DMD-mut was obtained by 
deletion of miR-31 binding sites. RLuc and FLuc activities were 
measured by Dual Glo luciferase assay (Promega). 
 
miRNA overexpression and sponge constructs.  
Plasmid pmiR-31 was produced by cloning a pri-miR-31 with 100 
nucleotides upstream and downstream from the pre-miRNA into the 
U1snRNA expression cassette (Denti et al, 2004). Sponge-31 
construct was generated by cloning-annealed oligonucleotides 
containing four artificial miR-31 binding sites into the WPRE SacII 
restriction site downstream from the green fluorescent protein open 
reading frame, according to Gentner et al., (2009).  
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miR-31 sponge was combined with exon skipping by cloning-
annealed oligos into the WPRE sequence of the green fluorescent 
protein reporter of lentiviral PCCL-U1#51 reported to induce 
skipping of DMD exon 51 (Incitti et al, 2010).  
 
Statistical analyses 
Each data shown in qRT-PCR is the result of at least three 
independent experiments. Data are shown as mean ± standard 
deviation (SD). Unless specifically stated, statistical significance of 
differences between means was assessed by two-tailed t-test and a p < 
0.05 was considered significant. 
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GLOSSARY 
 
BMD: Becker Muscular Dystrophy 
DAPC: Dystrophin Associated Protein Complex 
DYS: Dystrophin 
DMD: Duchenne Muscular Dystrophy 
GFP: Green Fluorescent Protein 
HDAC: Histon Deacetylase  
LNA: Locked Nuclei Acid 
mdx: murine model of Duchenne Muscular Dystrophy 
miR: microRNA 
mRNA: messenger RNA 
nNOS: neuronal Nitric Oxide Synthase 
snRNA: small nuclear RNA 
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